Home › Triple-Negative Breast Cancer › District of Columbia › Washington
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Washington, DC
Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Washington. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Nagre-recruitObservasyonal na pag-aaral
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Nagre-recruitPhase 3
- Washington Hospital Center ( Site 0098), Washington D.C.
- Holy Cross Hospital ( Site 0091), Silver Spring · 7 mi ang layo
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Nagre-recruitPhase 3
- Holy Cross Hospital ( Site 0069), Silver Spring · 7 mi ang layo
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Georgetown University Medical Center, Washington D.C.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Nagre-recruitPhase 3
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
Nagre-recruit
- National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
Nagre-recruitPhase 1
- Georgetown University Medical Center, Washington D.C.
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Nagre-recruitPhase 2
- National Institute of Health Clinical Center, Bethesda · 7 mi ang layo
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Nagre-recruitPhase 2
- Georgetown University Medical Center, Washington D.C.
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Nagre-recruitObservasyonal na pag-aaral
- George Washington University, Washington D.C.
Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod
- Houston, TX42 pag-aaral
- New York City, NY31 pag-aaral
- Nashville, TN28 pag-aaral
- Los Angeles, CA27 pag-aaral
- Boston, MA26 pag-aaral
- San Antonio, TX23 pag-aaral
- St. Louis, MO21 pag-aaral
- Arlington, VA20 pag-aaral
- Atlanta, GA20 pag-aaral
- Dallas, TX18 pag-aaral
- Chicago, IL16 pag-aaral
- Columbus, OH16 pag-aaral
Iba pang pag-aaral sa Washington
- Kanser (lahat ng uri)58 pag-aaral
- Non-Small Cell Lung Cancer55 pag-aaral
- Kanser sa Suso46 pag-aaral
- Metastatic Cancer43 pag-aaral
- Kanser sa Baga41 pag-aaral
- Kanser sa Prostate38 pag-aaral
- Obesity33 pag-aaral
- Colorectal Cancer29 pag-aaral
- Sakit sa Puso at Ugat ng Dugo28 pag-aaral
- Kanser sa Pantog26 pag-aaral
- Acute Myeloid Leukemia24 pag-aaral
- Kanser sa Ovary23 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.